Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839112 | 0.84 | CYP17A1 (0.38) | SYKCYP17A1TOP2ATOP2BEGLN2 | |
| SCHEMBL30013712 | 0.84 | CYP17A1 (0.38) | SYKCYP17A1TOP2ATOP2BEGLN2 | |
| SCHEMBL29883076 | 0.79 | SYK (0.39) | SYKCYP17A1TOP2ATOP2BEGLN2 | |
| SCHEMBL23608484 | 0.79 | SYK (0.39) | SYKCYP17A1TOP2ATOP2BEGLN2 | |
| SCHEMBL18820155 | 0.78 | SMARCA2 (0.59) | SYKCYP17A1CA12CA1CA9 | |
| SCHEMBL31042935 | 0.78 | CYP17A1 (0.40) | SYKCYP17A1TOP2ATOP2BEGLN2 | |
| SCHEMBL23580147 | 0.77 | SMARCA2 (0.37) | SMARCA2 | |
| SCHEMBL30493119 | 0.77 | BACE1 (0.35) | SYKCYP17A1TOP2ATOP2BCA12 | |
| SCHEMBL31745657 | 0.77 | BACE1 (0.35) | SYKCYP17A1TOP2ATOP2BCA12 | |
| SCHEMBL25839110 | 0.77 | BACE1 (0.35) | SYKCYP17A1TOP2ATOP2BCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4081526-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2021134004-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRODINGER, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | SYK 240/4885CYP17A1 353/4885TOP2A 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.